Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 9, 2016, Pages 5368-5378

  Lawitz, Eric J ^a   Dvory Sobol, Hadas ^b   Doehle, Brian P ^b   Worth, Angela S ^b   McNally, John ^b   Brainard, Diana M ^b   Link, John O ^b   Miller, Michael D ^b   Mo, Hongmei ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VELPATASVIR; VIRUS RNA; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC PATIENT; CONTROLLED STUDY; CROSS RESISTANCE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; EC50; FOLLOW UP; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION; WILD TYPE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS C, CHRONIC; MUTATION; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CARBAMATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; GENE EXPRESSION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; MUTATION; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84983503441     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00763-16     Document Type: Article

References (44)

1. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x.
2. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. 2013. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368:1878-1887. http://dx.doi.org/10.1056/NEJMoa1214853.
3. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR, Study P, Study F. 2013. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368:1867-1877. http://dx.doi.org/10.1056/NEJMoa1214854.
4. Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G. 2012. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 56: 1247-1253. http://dx.doi.org/10.1016/j.jhep.2011.12.033.
5. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. 2014. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483-1493. http://dx.doi.org/10.1056/NEJMoa1316366.
6. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Brau N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. 2014. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370:1889-1898. http://dx.doi.org/10.1056/NEJMoa1402454.
7. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW. 2014. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370:1879-1888. http://dx.doi.org/10.1056/NEJMoa1402355.
8. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. 2014. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370: 1594-1603. http://dx.doi.org/10.1056/NEJMoa1315722.
9. Sulkowski MS, Jacobson IM, Nelson DR. 2014. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 370:1560-1561. http://dx.doi.org/10.1056/NEJMc1401726.
10. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. 2015. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163:1-13. http://dx.doi.org/10.7326/M15-0785.
11. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318-327. http://dx.doi.org/10.1002/hep.26744.
12. Hissar SS, Goyal A, Kumar M, Pandey C, Suneetha PV, Sood A, Midha V, Sakhuja P, Malhotra V, Sarin SK. 2006. Hepatitis C virus genotype 3 predominates in north and central India and is associated with significant histopathologic liver disease. J Med Virol 78:452-458. http://dx.doi.org/10.1002/jmv.20561.
13. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F. 2011. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 31(Suppl 2):S61-S80. http://dx.doi.org/10.1111/j.1478-3231.2011.02540.x.
14. Cheng G, Tian Y, Yu M, Lee Y-J, Gong R, Trejo-Martin A, Peng B, Robinson M, Beran R, Bush C, Chan K, Nash M, Worth A, Yang H, Perry J, Taylor J, Yang C, Paulson M, Delaney W, Link JO. 2013. GS-5816, a second-generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage, and a high resistance barrier. EASL 48th Annu Meet, Amsterdam, The Netherlands, 24 to 28 April 2013. http://www.natap.org/2013/EASL/EASL-34.htm.
15. Lawitz E, Freilich B, Link J, German P, Mo H, Han L, Brainard DM, McNally J, Marbury T, Rodriguez-Torres M. 2015. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat 22:1011-1019. http://dx.doi.org/10.1111/jvh.12435.
16. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, Murphy KM. 2010. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 12:425-432. http://dx.doi.org/10.2353/jmoldx.2010.090188.
17. Hedskog C, Dvory-Sobol H, Gontcharova V, Martin R, Ouyang W, Han B, Gane EJ, Brainard D, Hyland RH, Miller MD, Mo H, Svarovskaia E. 2015. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat 22:871-881. http://dx.doi.org/10.1111/jvh.12405.
18. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V. 2015. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology 62:1623-1632. http://dx.doi.org/10.1002/hep.27934.
19. Sarrazin C. 2016. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64:486-504. http://dx.doi.org/10.1016/j.jhep.2015.09.011.
20. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins C, Pilot-Matias T. 2015. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A Antimicrob Agents Chemother 59:979-987. http://dx.doi.org/10.1128/AAC.04226-14.
21. Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, Gillum JM, Pierra C, Standring DN, Seifer M. 2014. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob Agents Chemother 58:4431-4442. http://dx.doi.org/10.1128/AAC.02777-13.
22. McPhee F, Hernandez D, Zhou N, Yu F, Ueland J, Monikowski A, Chayama K, Toyota J, Izumi N, Yokosuka O, Kawada N, Osaki Y, Hughes EA, Watanabe H, Ishikawa H, Kumada H. 2014. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther 19:479-490. http://dx.doi.org/10.3851/IMP2729.
23. Black S, Pak I, Ingravallo P, McMonagle P, Chase R, Shaughnessy M, Hwang P, Haber B, Harrigan PR, Brumme C, Hazuda D, Howe AYM. 2015. Resistance analysis of virologic failures in hepatitis C genotype 1-infected patients treated with grazoprevir + elbasvir ± ribavirin: the C-WORTHY study, abstr P0891. 50th Annu Meet EASL, Vienna, Austria, 22 to 26 April 2015. http://www.natap.org/2015/EASL/EASL-107.htm.
24. Ng T, Pilot-Matias T, Tripathi R, Schnell G, Reisch T, Beyer J, Dekhtyar T, Asatryan A, Mensa F, Campbell A, Kort J, Collins C. 2015. Analysis of HCV genotype 1 variants detected during monotherapy and combination therapy with next generation HCV direct-acting antiviral agents ABT-493 and ABT-530. 66th Annu Meet Am Assoc Study Liver Dis, 13 to 37 November 2015. http://www.natap.org/2015/AASLD/AASLD-25.htm.
25. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S, ASTRAL-1 Investigators. 2015. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373:2599-2607. http://dx.doi.org/10.1056/NEJMoa1512610.
26. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourliere M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M, ASTRAL-2 Investigators, ASTRAL-3 Investigators. 2015. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373:2608-2617. http://dx.doi.org/10.1056/NEJMoa1512612.
27. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS, Jr, Charlton M, ASTRAL-4 Investigators. 2015. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373:2618-2628. http://dx.doi.org/10.1056/NEJMoa1512614.
28. Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H. 2013. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 57:6333-6340. http://dx.doi.org/10.1128/AAC.02193-12.
29. Cheng G, Peng B, Corsa A, Yu M, Nash M, Lee YI, Xu Y, Kirschberg T, Tian Y, Taylor J, Link J, Delaney W, IV. 2012. Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885, abstr 1172. EASL 47th Annu Meet, Barcelona, Spain, 18 to 22 April 2012. http://www.natap.org/2012/EASL/EASL-62.htm.
30. Robinson M, Yang H, Sun SC, Peng B, Tian Y, Pagratis N, Greenstein AE, Delaney WE. 2010. Novel HCV reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob Agents Chemother 54:3099-3106. http://dx.doi.org/10.1128/AAC.00289-10.
31. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113. http://dx.doi.org/10.1126/science.285.5424.110.
32. Cheng G, Chan K, Yang H, Corsa A, Pokrovskii M, Paulson M, Bahador G, Zhong W, Delaney W. 2011. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. Antimicrob Agents Chemother 55:2197-2205. http://dx.doi.org/10.1128/AAC.01382-10.
33. Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney W, Cheng G. 2013. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. Antiviral Res 100:439-445. http://dx.doi.org/10.1016/j.antiviral.2013.08.018.
34. Peng B, Yu M, Xu S, Lee YJ, Tian Y, Yang H, Chan K, Mo H, McHutchison J, Delaney W, Cheng G. 2013. Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology 144: 59-61. http://dx.doi.org/10.1053/j.gastro.2012.09.033.
35. Shih IH, Vliegen I, Peng B, Yang H, Hebner C, Paeshuyse J, Purstinger G, Fenaux M, Tian Y, Mabery E, Qi X, Bahador G, Paulson M, Lehman LS, Bondy S, Tse W, Reiser H, Lee WA, Schmitz U, Neyts J, Zhong W. 2011. Mechanistic characterization of GS-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 55:4196-4203. http://dx.doi.org/10.1128/AAC.00307-11.
36. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, II, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100. http://dx.doi.org/10.1038/nature08960.
37. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. 2012. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 57:24-31. http://dx.doi.org/10.1016/j.jhep.2011.12.029.
38. Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM. 2008. Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol 82:1073-1083. http://dx.doi.org/10.1128/JVI.00328-07.
39. Fridell RA, Wang C, Sun JH, O'Boyle DR, II, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M. 2011. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54:1924-1935. http://dx.doi.org/10.1002/hep.24594.
40. Mayers D, Vince B, Hill J, Lawitz E, O'Riordan W, Webster L, Gruener D, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bolyai JZ, Zhou XJ. 2012. IDX719, HCV NS5A inhibitor, demonstrates pan-genotypic activity after three days of monotherapy in genotype 1, 2, 3 or 4 HCV infected patients. 63rd Annu Meet Am Assoc Study Liver Dis, Boston, MA, 9 to 13 November 2012. http://www.natap.org/2013/HCV/013113-03.htm.
41. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson IM, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Eley T, Wind-Rotolo M, Huang S-P, Gao M, McPhee F, Sherman E, Hindes R, Symonds WT, Pasquinelli C, Grasela DM, AI444040 Study Group. 2012. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with our without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. 63rd Annu Meet Am Assoc Study Liver Dis, 9 to 13 November 2012. http://www.natap.org/2012/AASLD/AASLD-06.htm.
42. Patiño-Galindo JA, Salvatierra K, Gonzalez-Candelas F, Lopez-Labrador FX. 2016. Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. Antimicrob Agents Chemother 60:2402-2416. http://dx.doi.org/10.1128/AAC.02776-15.
43. Dvory-Sobol H, Wong KA, Ku KS, Bae A, Lawitz EJ, Pang PS, Harris J, Miller MD, Mo H. 2012. Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients. Antimicrob Agents Chemother 56:5289-5295. http://dx.doi.org/10.1128/AAC.00780-12.
44. Dvory-Sobol H, Voitenleitner C, Mabery E, Skurnac T, Lawitz EJ, McHutchison J, Svarovskaia ES, Delaney W, Miller MD, Mo H. 2014. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 58:6599-6606. http://dx.doi.org/10.1128/AAC.02815-14.